MINTEZOL
LOE ApproachingNDAORALTABLET, CHEWABLEPriority Review
Approved
Apr 1967
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 7h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MINTEZOL is an oral anthelmintic medication approved in 1967 by Merck & Co. for the treatment of parasitic worm infections. The drug is formulated as chewable tablets for convenient oral administration. Mechanism of action and specific indications are not disclosed in available data.
LOE Approaching
With loss of exclusivity approaching, the brand team is likely focused on defending market share against generic competition with moderate competitive pressure (30/100).
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MINTEZOL offers limited career growth given the approaching LOE and zero linked job openings. Positions on this product are typically focused on defensive strategies, compliance, and managing the transition to generic competition rather than growth initiatives.
Brand ManagerField Sales Representative
Worked on MINTEZOL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.